Back to List View Graph View

Temozolomide

Temozolomide (TMZ) is an oral alkylating chemotherapeutic agent widely used in the treatment of malignant brain tumors, most notably glioblastoma multiforme (GBM) and other high-grade gliomas.

Where the papers sit

30 papers from the last 6 months study temozolomide directly · updated from PubMed 16 Nov 2026

  • Glioblastoma Resistance Mechanisms

    Resistance in glioblastoma is shifting from an MGMT-centered explanation toward actionable tumor and microenvironmental mechanisms. MET–YANK2–NEDD4L, USP5–RSK1, METTL3–CBX5 and O-GlcNAcylation recur as drivers, while stress granules and neuronal nitric oxide synthase offer vulnerabilities. Organoids and 3D models support personalized testing, and siRNA, photothermal platforms and combination treatments aim to restore temozolomide response. Hyperglycemia and MGMT-negative disease remain important contexts for validation.

    12 papers · 40%

  • Glioma Treatment and Grading

    Clinical management is moving toward molecularly and grade-adapted glioma treatment rather than a single temozolomide standard. Randomized data compare temozolomide with radiotherapy in low-grade glioma, while cohort studies address high-risk grade 2 disease, pediatric H3K27M tumors and recurrent treatment. MGMT promoter methylation stability supports biomarker-guided rechallenge, but ERP44, β-catenin, PI3K/AKT and SLC31A1 point to additional resistance biology. Toxicity detection and care remain central to treatment decisions.

    9 papers · 30%

  • Brain Tumor Drug Delivery

    Brain-tumor delivery is moving toward carrier-enabled and route-specific temozolomide combination therapy. Ionizable and solid-lipid nanoparticles are being used to package nucleic acids or co-deliver carmustine, while intranasal administration seeks to bypass systemic and blood–brain barriers. Focused ultrasound is being developed to increase tumor exposure with quantitative, translational pharmacokinetic guidance. The evidence remains preclinical, centered on mice and delivery optimization rather than clinical efficacy.

    3 papers · 10%

  • Others — Cancer Progression and Therapy

    Cancer progression and treatment form the dominant theme, but the set also includes DMD pathogenesis, nasopharyngeal carcinoma and neuroblastoma. Glioblastoma studies emphasize cell-cycle arrest, apoptosis, invasion and immune-microenvironment remodeling. Trichodermin and UFMylation inhibition are being explored as therapies, while NCOA3 and related molecular features support prognostic stratification. Because the diseases and biological questions diverge, no unified therapeutic direction is established.

    6 papers · 20%

NEW DIRECTION

Temozolomide is repurposed as a disease-modifying treatment for Duchenne muscular dystrophy

The Duchenne muscular dystrophy study in mdx mice treats temozolomide not as an antitumor drug but as a pharmacological candidate identified by its ability to reverse an ATP6AP2-associated disease signature; administration improved motor coordination, balance, and grip strength while preserving muscle architecture and reducing necrosis and fibrosis 42594836Aug. This assigns temozolomide a role outside the set’s cancer-treatment applications and suggests a therapeutic direction in which it targets molecular and tissue features of muscular dystrophy rather than tumor cells.

temozolomide chemical structure

Papers

The 30 papers from the last 6 months that study temozolomide directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Glioblastoma Resistance Mechanisms (12)
  1. METTL3 Increases Temozolomide Resistance in MGMT-Negative Glioblastoma by Enhancing CBX5 mRNA Stability in an m6A-IGF2BP2-Dependent Manner. CNS neuroscience & therapeutics · 1 Oct 2026 PMID 42817804
  2. USP5 stabilizes RSK1 and promotes temozolomide resistance in glioblastoma. Biochemical and biophysical research communications · 24 Aug 2026 PMID 42636771
  3. Exploring the antidepressant-like effects of cannabidiol and/or temozolomide in female mice with induced glioblastoma. Neuroscience · 15 Aug 2026 PMID 42603608
  4. Targeting Temozolomide-Resistant Glioblastoma: Therapeutic Potential of Neuronal Nitric Oxide Synthase Inhibitor. Cancer medicine · 30 Jun 2026 PMID 42374654
  5. MET-mediated phosphorylation of YANK2 at Y282 inhibits NEDD4L-dependent SUMOylation and degradation, promoting chemoresistance in glioblastoma. Molecular biomedicine · 23 Jun 2026 PMID 42337173
  6. Fe3+-responsive aggregable gold nanoplatform enables siRNA-mediated chemoresistance reversal and combined photothermal-temozolomide therapy for glioblastoma. Acta biomaterialia · 18 Jun 2026 PMID 42315000
  7. Patient-derived organoids predict personalized drug response and reveal alternative therapeutic options in glioblastoma. Cell reports. Medicine · 11 Jun 2026 PMID 42276053
  8. The WYZ-1 mouse glioblastoma stem cell model: A novel preclinical tool for tumor and therapy studies. Cancer letters · 9 Jun 2026 PMID 42263837
  9. Dual-functional MXene-integrated GelMA microspheres for synergistic chemo/photothermal therapy: In vitro 2D/3D multi-cancer evaluation and in vivo breast cancer validation. International journal of biological macromolecules · 7 Jun 2026 PMID 42251874
  10. Hyperglycemia promotes O-GlcNAcylation-dependent vulnerability and modulates temozolomide response in glioblastoma. Biochemical and biophysical research communications · 5 Jun 2026 PMID 42247812
  11. Stress granule assembly represents a therapeutic vulnerability in super-enhancer-driven circMLB-mediated glioblastoma temozolomide resistance. Cancer letters · 21 May 2026 PMID 42167397
  12. Comprehensive quantum chemical analysis, vibrational spectroscopy, molecular docking, ADMET, and in vitro validation studies of hydroxychloroquine-MRGPRX2 complex in IDH-wildtype glioblastoma. PloS one · 21 May 2026 PMID 42166475
Glioma Treatment and Grading (9)
  1. Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge. Journal of neuro-oncology · 16 Sept 2026 PMID 42747707
  2. ERP44 Is Associated With Poor Prognosis and Promotes Proliferation and Temozolomide Resistance in Lower-grade Glioma. Cancer genomics & proteomics · 31 Aug 2026 PMID 42674822
  3. Multifaceted Temozolomide Toxicity in Glioma: Detection & Care. La Clinica terapeutica · 28 Aug 2026 PMID 42664125
  4. IFIT3 silencing improves the sensitivity of gliomas to temozolomide by inactivating the PI3K/AKT signaling pathway. Behavioural brain research · 15 Aug 2026 PMID 42603632
  5. Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU). Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2 Jul 2026 PMID 42391581
  6. Hsa-miR-25-3p Inhibition Sensitizes Patient-Derived Glioblastoma Cells to Temozolomide via β-catenin Downregulation. Cellular and molecular neurobiology · 30 May 2026 PMID 42218313
  7. Efficacy of chemoradiotherapy in pediatric H3K27M-mutant diffuse intrinsic pontine glioma: a study based on single-center and SEER data. Journal of neuro-oncology · 30 May 2026 PMID 42218248
  8. Implications of the Cuproptosis Protein SLC31A1 for the Immune Microenvironment and Temozolomide Sensitivity in Glioblastoma. Anticancer research · 27 May 2026 PMID 42203322
  9. Treatment patterns and outcomes in high-risk WHO grade 2 diffuse glioma: a multicentre retrospective cohort study. Journal of neuro-oncology · 20 May 2026 PMID 42159820
Brain Tumor Drug Delivery (3)
  1. Dual-drug conjugated ionizable lipids for nucleic acid delivery and multidimensional targeted therapy of brain tumors. International journal of pharmaceutics · 27 Sept 2026 PMID 42801996
  2. Intranasal Delivery of Solid Lipid Nanoparticles Loaded with Carmustine and Temozolomide for Glioblastoma Treatment in Mice. AAPS PharmSciTech · 23 Sept 2026 PMID 42778815
  3. Focused Ultrasound-Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling. Clinical cancer research : an official journal of the American Association for Cancer Research · 27 Aug 2026 PMID 42658183
Others — Cancer Progression and Therapy (6)
  1. ATP6AP2 dysregulation as a central hub in DMD pathogenesis: An integrated multi-omics and therapeutic study. International immunopharmacology · 13 Aug 2026 PMID 42594836
  2. Integrated profiling identifies NCOA3 as a prognostic factor in patients with glioma. Functional & integrative genomics · 13 Aug 2026 PMID 42587220
  3. Long-Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group. Pediatric blood & cancer · 23 Jul 2026 PMID 42487540
  4. Trichodermin exhibits potent anti-glioblastoma activity by inducing cell cycle arrest and apoptosis, suppressing invasion, and enhancing temozolomide efficacy. Journal of enzyme inhibition and medicinal chemistry · 20 Jul 2026 PMID 42474259
  5. Dual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression. Signal transduction and targeted therapy · 19 Jul 2026 PMID 42472853
  6. Downregulation of SLC44A4 in nasopharyngeal carcinoma is associated with malignant progression, B-cell/TLS-related immune features, and sensitivity to DNA-damaging agents. PloS one · 26 Jun 2026 PMID 42361082

By study type

Clinical trials (1)
  1. Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU). Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2 Jul 2026 PMID 42391581
Observational studies and case reports (4)
  1. Multifaceted Temozolomide Toxicity in Glioma: Detection & Care. La Clinica terapeutica · 28 Aug 2026 PMID 42664125
  2. Long-Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group. Pediatric blood & cancer · 23 Jul 2026 PMID 42487540
  3. Efficacy of chemoradiotherapy in pediatric H3K27M-mutant diffuse intrinsic pontine glioma: a study based on single-center and SEER data. Journal of neuro-oncology · 30 May 2026 PMID 42218248
  4. Treatment patterns and outcomes in high-risk WHO grade 2 diffuse glioma: a multicentre retrospective cohort study. Journal of neuro-oncology · 20 May 2026 PMID 42159820
Human data, design not indexed (1)
  1. Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge. Journal of neuro-oncology · 16 Sept 2026 PMID 42747707
Preclinical: animal, cell and lab studies (22)
  1. METTL3 Increases Temozolomide Resistance in MGMT-Negative Glioblastoma by Enhancing CBX5 mRNA Stability in an m6A-IGF2BP2-Dependent Manner. CNS neuroscience & therapeutics · 1 Oct 2026 PMID 42817804
  2. Intranasal Delivery of Solid Lipid Nanoparticles Loaded with Carmustine and Temozolomide for Glioblastoma Treatment in Mice. AAPS PharmSciTech · 23 Sept 2026 PMID 42778815
  3. ERP44 Is Associated With Poor Prognosis and Promotes Proliferation and Temozolomide Resistance in Lower-grade Glioma. Cancer genomics & proteomics · 31 Aug 2026 PMID 42674822
  4. Focused Ultrasound-Enhanced Drug Delivery to Brain Tumors: Quantitative and Translational Insights from CNS Physiologically Based Pharmacokinetic Modeling. Clinical cancer research : an official journal of the American Association for Cancer Research · 27 Aug 2026 PMID 42658183
  5. USP5 stabilizes RSK1 and promotes temozolomide resistance in glioblastoma. Biochemical and biophysical research communications · 24 Aug 2026 PMID 42636771
  6. IFIT3 silencing improves the sensitivity of gliomas to temozolomide by inactivating the PI3K/AKT signaling pathway. Behavioural brain research · 15 Aug 2026 PMID 42603632
  7. Exploring the antidepressant-like effects of cannabidiol and/or temozolomide in female mice with induced glioblastoma. Neuroscience · 15 Aug 2026 PMID 42603608
  8. Integrated profiling identifies NCOA3 as a prognostic factor in patients with glioma. Functional & integrative genomics · 13 Aug 2026 PMID 42587220
  9. Trichodermin exhibits potent anti-glioblastoma activity by inducing cell cycle arrest and apoptosis, suppressing invasion, and enhancing temozolomide efficacy. Journal of enzyme inhibition and medicinal chemistry · 20 Jul 2026 PMID 42474259
  10. Dual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression. Signal transduction and targeted therapy · 19 Jul 2026 PMID 42472853
  11. Targeting Temozolomide-Resistant Glioblastoma: Therapeutic Potential of Neuronal Nitric Oxide Synthase Inhibitor. Cancer medicine · 30 Jun 2026 PMID 42374654
  12. Downregulation of SLC44A4 in nasopharyngeal carcinoma is associated with malignant progression, B-cell/TLS-related immune features, and sensitivity to DNA-damaging agents. PloS one · 26 Jun 2026 PMID 42361082
  13. MET-mediated phosphorylation of YANK2 at Y282 inhibits NEDD4L-dependent SUMOylation and degradation, promoting chemoresistance in glioblastoma. Molecular biomedicine · 23 Jun 2026 PMID 42337173
  14. Fe3+-responsive aggregable gold nanoplatform enables siRNA-mediated chemoresistance reversal and combined photothermal-temozolomide therapy for glioblastoma. Acta biomaterialia · 18 Jun 2026 PMID 42315000
  15. Patient-derived organoids predict personalized drug response and reveal alternative therapeutic options in glioblastoma. Cell reports. Medicine · 11 Jun 2026 PMID 42276053
  16. The WYZ-1 mouse glioblastoma stem cell model: A novel preclinical tool for tumor and therapy studies. Cancer letters · 9 Jun 2026 PMID 42263837
  17. Dual-functional MXene-integrated GelMA microspheres for synergistic chemo/photothermal therapy: In vitro 2D/3D multi-cancer evaluation and in vivo breast cancer validation. International journal of biological macromolecules · 7 Jun 2026 PMID 42251874
  18. Hyperglycemia promotes O-GlcNAcylation-dependent vulnerability and modulates temozolomide response in glioblastoma. Biochemical and biophysical research communications · 5 Jun 2026 PMID 42247812
  19. Hsa-miR-25-3p Inhibition Sensitizes Patient-Derived Glioblastoma Cells to Temozolomide via β-catenin Downregulation. Cellular and molecular neurobiology · 30 May 2026 PMID 42218313
  20. Implications of the Cuproptosis Protein SLC31A1 for the Immune Microenvironment and Temozolomide Sensitivity in Glioblastoma. Anticancer research · 27 May 2026 PMID 42203322
  21. Stress granule assembly represents a therapeutic vulnerability in super-enhancer-driven circMLB-mediated glioblastoma temozolomide resistance. Cancer letters · 21 May 2026 PMID 42167397
  22. Comprehensive quantum chemical analysis, vibrational spectroscopy, molecular docking, ADMET, and in vitro validation studies of hydroxychloroquine-MRGPRX2 complex in IDH-wildtype glioblastoma. PloS one · 21 May 2026 PMID 42166475
Unclassified: not yet indexed with MeSH (2)
  1. Dual-drug conjugated ionizable lipids for nucleic acid delivery and multidimensional targeted therapy of brain tumors. International journal of pharmaceutics · 27 Sept 2026 PMID 42801996
  2. ATP6AP2 dysregulation as a central hub in DMD pathogenesis: An integrated multi-omics and therapeutic study. International immunopharmacology · 13 Aug 2026 PMID 42594836